Michael G. Raab
President, CEO & DirectorMr. Michael G. Raab, also known as Mike, has been the Chief Executive Officer and President of Ardelyx, Inc. since March 2009. He was an Independent Chairman of the Board of Tempest Therapeutics Inc. since June 25, 2021 until February 03, 2025 and served as its Independent Director from June 25, 2021 to May 22, 2026. Mr. Raab was a Venture Partner of New Enterprise Associates (NEA) from June 2002 to 2009. Prior to NEA, he served as Senior Vice President of Therapeutics and General Manager of Renagel of Genzyme Corp. from 1999 to 2002. From 1998 to 1999, he served as Vice President of Business Development at the Therapeutics Division of Genzyme, responsible for the identification and in licensing of new therapeutic product opportunities. Mr. Raab gained extensive international experience while building a commercial operation in Latin American at the Therapeutics and Surgical Products groups for it. From 1994 to 1996, Mr. Raab served as Product Manager of Ceredase. He served for two years in the Diagnostic Products and Services Division of Genzyme. He served as Sales and Marketing Executive at Repligen Corporation and Bristol-Myers Squibb Co. He is also actively involved with 23andMe, Trine Pharmaceuticals and Vitae Pharmaceuticals. He served as Chairman of Ardelyx, Inc. since March 2009. He had been an Independent Director of Amicus Therapeutics, Inc. since May 2004 until April 27, 2026 and was its Lead Independent Director since September 11, 2018 until March 4, 2024 and served as its Chairman since March 4, 2024 until April 27, 2026. He serves as a Director of Macroflux Corp., Progen Pharmaceuticals, Inc. and Zosano Pharma, Inc. He has been a Director of Ardelyx, Inc. since 2008. Mr. Raab has significant experience in drug development and commercialization of products in the rare diseases, cardio renal and GI diseases. He served as a Director at Novalar Pharmaceuticals, Inc. since November 2007. He served as Director of Intarcia Therapeutics Inc., (Formerly Known as BioMedicines, Inc.) since July 2003. He served as a Board Observer at Liquidia Corporation. He serves as a Member of the Life Sciences Advisory Board at Silicon Valley Bank. He served as Director of Liquidia Corporation. He served as Director of Hyperion Therapeutics, Inc. He served as an Independent Director of Novacea Inc. since October 2002. He received a Bachelor of Arts in Communications from DePauw University. Mr. Raab serves as a member of the board of directors of the California Life Sciences Association, a non-profit trade association serving the life science industry in California and as a member of the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization.
Positions
- Company NameArdelyx, Inc.Stock CodeARDXPositionPresident, CEO & DirectorColleagues
- DMDavid M. MottIndependent Chairman of the Board
- SHSue HohenleitnerChief Financial Officer
- JBJohn BishopChief Technical & Quality Officer
- JRJoseph ReillySenior VP of Finance & Principal Accounting Officer
- LMLisa M. CaperelliSenior Vice President of Investor Relations and Corporate Communications
- RJRichard J. RodgersIndependent Director
- WCWilliam Charles A. BertrandIndependent Director
- RBRobert B. BazemoreIndependent Director
